Regional Analysis

Global Eye Inflammation Treatment Market – Regional Analysis

On the basis of region, the global eye inflammation treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa

Among regions, North America eye inflammation treatment market is expected to hold a dominant position during the forecast period, owing to increasing product approvals by regulatory authorities. For instance, on February 02, 2022, the U.S. Food and Drug Administration has approved the first generic version of Restasis, a cyclosporine ophthalmic emulsion, 0.05% single-use vials eye drops planned to boost tear production in patients whose tear production is thought to be suppressed because of ocular inflammation linked to keratoconjunctivitis sicca, a dry eye condition.

Furthermore, Europe is also estimated to witness significant growth in the global eye inflammation treatment market, owing to increasing recommendation by regulatory bodies of marketing of eye disease treatment drugs in Europe. For instance, in May 2017, The European Medicines Agency has recommended granting a marketing authorisation in the European Union for Oxervate, a cenegermin for the treatment of moderate or severe neurotrophic keratitis, an unusual eye disease that can lead to loss of sight.

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa